TargetMol

Atomoxetine

Product Code:
 
TAR-T20886
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T20886-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20886-10mg10mg£1,034.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20886-25mg25mg£1,998.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Atomoxetine is a selective inhibitor of noradrenaline reuptake.
CAS:
83015-26-3
Formula:
C17H21NO
Molecular Weight:
255.361
Pathway:
Neuroscience
Purity:
0.98
SMILES:
CNCC[C@@H](Oc1ccccc1C)c1ccccc1
Target:
Norepinephrine

References

1. Mosholder AD, Taylor L, Mannheim G, Ortendahl L, Woodworth TS, Toh S. Incidence of Heart Failure and Cardiomyopathy Following Initiation of Medications for Attention-Deficit/Hyperactivity Disorder: A Descriptive Study. J Clin Psychopharmacol. 2018 Aug 10. doi: 10.1097/JCP.0000000000000939. [Epub ahead of print] PubMed PMID: 30102629. 2. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Aug 7. pii: S2215-0366(18)30269-4. doi: 10.1016/S2215-0366(18)30269-4. [Epub ahead of print] PubMed PMID: 30097390. 3. Froehlich T, Fogler J, Barbaresi WJ, Elsayed NA, Evans SW, Chan E. Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review. Clin Pharmacol Ther. 2018 Jul 27. doi: 10.1002/cpt.1192. [Epub ahead of print] Review. PubMed PMID: 30053315. 4. van den Brink RL, Nieuwenhuis S, Donner TH. Amplification and Suppression of Distinct Brain-wide Activity Patterns by Catecholamines. J Neurosci. 2018 Jul 23. pii: 0514-18. doi: 10.1523/JNEUROSCI.0514-18.2018. [Epub ahead of print] PubMed PMID: 30037827.